Von Willebrand Factor in Thrombotic Thrombocytopenic Purpura

 

 Buy Article Permissions and Reprints

Introduction

Thrombotic thrombocytopenic purpura (TTP), a disseminated form of thrombotic microangiopathy, was initially described by Moschcowitz in 1924.¹ TTP is defined by a pentad of findings, including severe thrombocytopenia, intravascular hemolysis with erythrocyte fragmentation, neurologic deficit, renal dysfunction, and fever.^2–4 The thrombocytopenia occurs in the presence of normal or even increased numbers of megakaryocytes in the bone marrow, suggesting increased consumption. Platelet aggregates, found in the microcirculation, contain little if any fibrin polymers, indicating that activation of coagulation and fibrin formation may be secondary and limited in extent.

About one-third of patients experience recurrent acute episodes at irregular and unpredictable intervals, whereas the majority of patients who recover from an acute TTP event experience no relapse and no persistent organ failure. TTP is usually classified as relapsing if complete remissions occurred between acute events and as chronic if complete recovery did not occur between bouts.

Genetic predisposition to TTP has been shown in several siblings suffering from recurrent TTP.⁵ Thus, cases of TTP can be further divided according to whether the disease has a familial or genetic component or is not heritable. Acute episodes of TTP may be triggered by viral or bacterial infection, autoimmune disorders, bone marrow transplantation, drug therapy, cancer, chemotherapy, and pregnancy.^3,4 The incidence of TTP is estimated to be two to eight cases per million people per year.^3,6 Until four decades ago, the mortality rate was virtually 100% but has since decreased to less than 20% after introduction of plasma therapy. Still, there were more than 4,500 TTP-associated deaths recorded in the United States between 1968 and 1991.⁶

• References

• 1 Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc NY Pathol Soc 1924; 24: 21-24.
  PubMedGoogle Scholar
• 2 Moake JL. Studies on the pathophysiology of thrombotic thrombocytopenic purpura. Sem Hematol 1997; 34: 83-89.
  PubMedGoogle Scholar
• 3 Moake JL, Chow TW. Thrombotic thrombocytopenic purpura: Understanding a disease no longer rare. Am J Med Sci 1998; 316: 105-119.
  PubMedGoogle Scholar
• 4 Ruggenenti P, Remuzzi G. The pathophysiology and management of thrombotic thrombocytopenic purpura. Eur J Haematol 1996; 56: 191-207.
  PubMedGoogle Scholar
• 5 Wallace DC, Lovric A, Clubb JS, Carseldine DB. Thrombotic thrombocytopenic purpura in four siblings. Am J Med 1975; 38: 724-734.
  PubMedGoogle Scholar
• 6 Török TJ, Holman RC, Chorba TL. Increasing mortality from thrombotic thrombocytopenic purpura in the United States–analysis of national mortality data. Am J Hematol 1995; 50: 89-90.
  PubMedGoogle Scholar
• 7 Siddiqui FA, Lian EC-Y. Novel platelet-agglutinating protein from a thrombotic thrombocytopenic purpura plasma. J Clin Invest 1985; 76: 1330-1337.
  CrossrefPubMedGoogle Scholar
• 8 Murphy WG, Moore JC, Kelton JG. Calcium-dependent cysteine protease activity in the sera of patients with thrombotic thrombocytopenic purpura. Blood 1987; 70: 1683-1687.
  PubMedGoogle Scholar
• 9 Kelton JG, Moore JC, Warkentin TE, Hayward CP. Isolation and characterization of cysteine proteinase in thrombotic thrombocytopenic purpura. Br J Haematol 1996; 93: 421-426.
  CrossrefPubMedGoogle Scholar
• 10 Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, Seder RH, Suchen LH, Deykin D. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432-1435.
  CrossrefPubMedGoogle Scholar
• 11 Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986; 78: 1456-1461.
  CrossrefPubMedGoogle Scholar
• 12 Furlan M, Stieger J, Beck EA. Exposure of platelet binding sites in von Willebrand factor by adsorption onto polystyrene latex particles. Biochim Biophys Acta 1987; 924: 27-37.
  CrossrefPubMedGoogle Scholar
• 13 Slayter H, Loscalzo J, Bockenstedt P, Handin RI. Native conformation of human von Willebrand factor. Analysis by electron microscopy and quasi-elastic light scattering. J Biol Chem 1985; 260: 8559-8563
  PubMedGoogle Scholar
• 14 Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell 1986; 46: 185-190.
  CrossrefPubMedGoogle Scholar
• 15 Tsai H-M, Nagel RL, Hatcher VB, Sussman II. Multimeric composition of endothelial cell-derived von Willebrand factor. Blood 1989; 73: 2074-2076.
  PubMedGoogle Scholar
• 16 Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 1994; 83: 2171-179.
  PubMedGoogle Scholar
• 17 Dent JA, Galbusera M, Ruggeri ZM. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J Clin Invest 1991; 88: 774-777.
  CrossrefPubMedGoogle Scholar
• 18 Furlan M, Robles R, Affolter D, Meyer D, Baillod P, Lämmle B. Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers. Proc Natl Acad Sci USA 1993; 90: 7503-7507.
  CrossrefPubMedGoogle Scholar
• 19 Zimmerman TS, Dent JA, Ruggeri ZM, Nannini LH. Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE). J Clin Invest 1986; 77: 947-951
  CrossrefPubMedGoogle Scholar
• 20 Battle J, Lopez Fernandez MF, Campos M, Justica B, Berges C, Navarro JL, Diaz Cremades JM, Kasper CK, Dent JA, Ruggeri ZM, Zimmerman TS. The heterogeneity of type IIA von Willebrand’s disease: studies with protease inhibitors. Blood 1986; 68: 1207-1212.
  PubMedGoogle Scholar
• 21 Berkowitz SD, Dent J, Roberts J, Fujimura Y, Plow EF, Titani K, Ruggeri ZM, Zimmerman TS. Epitope mapping of the von Willebrand factor subunit distinguishes fragments present in normal and type IIA von Willebrand disease from those generated by plasmin. J Clin Invest 1987; 79: 524-531.
  CrossrefPubMedGoogle Scholar
• 22 Hamilton KK, Fretto LJ, Grierson DS, McKee PA. Effects of plasmin on von Willebrand factor multimers. Degradation in vitro and stimulation of release in vivo. J Clin Invest 1985; 76: 261-270.
  CrossrefPubMedGoogle Scholar
• 23 Thompson EA, Howard MA. Proteolytic cleavage of human von Willebrand factor induced by enzyme(s) released from polymorphonuclear cells. Blood 1986; 67: 1281-1285.
  PubMedGoogle Scholar
• 24 Tsai H-M, Nagel RL, Hatcher VB, Sussman II. Endothelial cell-derived high molecular weight von Willebrand factor is converted into the plasma multimer patterns by granulocyte proteases. Biochem Biophys Res Commun 1989; 158: 980-985.
  CrossrefPubMedGoogle Scholar
• 25 Kunicki TJ, Montgomery RR, Schullek J. Cleavage of human von Willebrand factor by platelet calcium-activated protease. Blood 1985; 65: 352-356.
  PubMedGoogle Scholar
• 26 Berkowitz SD, Nozaki H, Titani K, Murachi T, Plow EF, Zimmerman TS. Evidence that calpains and elastase do not produce the von Willebrand factor fragments present in normal plasma and IIA von Willebrand disease. Blood 1988; 72: 721-727.
  PubMedGoogle Scholar
• 27 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-4234.
  PubMedGoogle Scholar
• 28 Tsai H-M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87: 4235-4244.
  PubMedGoogle Scholar
• 29 Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand disease. Proc Natl Acad Sci USA 1990; 87: 6306-6310.
  CrossrefPubMedGoogle Scholar
• 30 Mannucci PM, Lombardi R, Lattuada A, Ruggenenti P, Vigano GL, Barbui T, Remuzzi G. Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Blood 1989; 74: 978-983.
  PubMedGoogle Scholar
• 31 Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097-3103.
  PubMedGoogle Scholar
• 32 Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lämmle B. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolyticuremic syndrome. N Engl J Med 1998; 339: 1578-1584.
  CrossrefPubMedGoogle Scholar
• 33 Moore JC, Murphy WG, Kelton JG. Calpain proteolysis of von Willebrand factor enhances its binding to platelet membrane glycoprotein IIb/IIIa: an explanation for platelet aggregation in thrombotic thrombocytopenic purpura. Br J Haematol 1990; 74: 457-464.
  CrossrefPubMedGoogle Scholar
• 34 Chow TW, Turner NA, Chintagumpala M, McPherson PD, Nolasco LH, Rice L, Hellums JD, Moake JL. Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura. Am J Hematol 1998; 57: 293-302.
  CrossrefPubMedGoogle Scholar
• 35 Moake JL, Byrnes JJ, Troll JH, Rudy CK, Hong SL, Weinstein MJ, Colannino NM. Effects of fresh-frozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1985; 65: 1232-1236.
  PubMedGoogle Scholar
• 36 Frangos JA, Moake JL, Nolasco L, Phillips MD, McIntire LV. Cryosupernatant regulates accumulation of unusually large vWF multimers from endothelial cells. Am J Physiol 1989; 256: H1635-1644.
  PubMedGoogle Scholar
• 37 Furlan M, Robles R, Solenthaler M, Lämmle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998; 91: 2839-2846.
  PubMedGoogle Scholar
• 38 Moake JL, Rudy CK, Troll JH, Schafer AI, Weinstein MJ, Colannino NM, Hong SL. Therapy of chronic relapsing thrombotic thrombocytopenic purpura with prednisone and azathio-prine. Am J Hematol 1985; 20: 73-79.
  CrossrefPubMedGoogle Scholar
• 39 Gaddis TG, Guthrie TH, Drew MJ, Sahud M, Howe RB, Mittelman A. Treatment of plasma refractory thrombotic thrombocytopenic purpura with protein A immunoabsorption. Am J Hematol 1997; 55: 55-58.
  CrossrefPubMedGoogle Scholar
• 40 Tsai H-M, Lian EC-Y. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594.
  CrossrefPubMedGoogle Scholar
• 41 Gasser C, Gautier E, Steck A, Siebenmann RE, Oechslin R. Hämolytisch-urämische Syndrome: bilaterale Nierenrinden-nekrosen bei akuten erworbenen hämolytischen Anämien. Schweiz Med Wochenschr 1955; 85: 905-909.
  PubMedGoogle Scholar
• 42 Harel Y, Silva M, Giroir B, Weinberg A, Cleary TB, Beutler B. A reporter transgene indicates renal-specific induction of tumor necrosis factor (TNF) by shiga-like toxin: Possible involvement of TNF in hemolytic uremic syndrome. J Clin Invest 1993; 92: 2110-2116.
  CrossrefPubMedGoogle Scholar
• 43 Byrnes JJ, Khurana M. Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med 1977; 297: 1386-1389.
  CrossrefPubMedGoogle Scholar
• 44 Moake JL, Chintagumpala M, Turner N, McPherson P, Nolasco L, Steuber C, Santiago-Borrero P, Horowitz M, Pehta J. Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura. Blood 1994; 84: 490-497.
  PubMedGoogle Scholar
• 45 Furlan M, Robles R, Morselli B, Sandoz P, Lämmle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1999; 81: 8-13.
  Article in Thieme ConnectPubMedGoogle Scholar